New hormone therapies before surgery may improve outcomes in high-risk prostate cancer
For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with surgery, suggests a ...